Navigation Links
Cepheid to Webcast Upcoming Financial Presentations
Date:8/26/2009

SUNNYVALE, Calif., Aug. 26 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced that its executives will be speaking at the following investor conferences, and invited investors to participate via webcast.

           Thomas Weisel Partners Healthcare Conference, Boston, MA
           Wednesday, 9 September, 2009, at 8.35 a.m. Eastern Time

           R. W. Baird 2009 Health Care Conference, New York, NY
           Thursday, 10 September, 2009, at 9.30 a.m. Eastern Time

           ThinkEquity Annual Growth Conference, San Francisco, CA
           Wednesday, 16 September, 2009, at 12.45 p.m. Pacific Time

           UBS  Global Life Sciences Conference, New York, NY
           Tuesday, 22 September, 2009, at 2.30 p.m. Eastern Time

Accessing Webcasts

To access the live webcasts for these events, please visit Cepheid's website at www.cepheid.com/investors at least 15 minutes before the schedule start time to download any necessary audio or plug-in software. A replay of the webcast will be available shortly following the presentation and will remain available for at least 90 days.

About Cepheid

Cepheid (Nasdaq: CPHD), based in Sunnyvale, Calif., is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The Company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Cepheid's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the Company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market.

    CONTACTS:
    For Media Inquiries:                     For Investor Inquiries:
    Jared Tipton                             Jacquie Ross
    Cepheid Corporate Communications         Cepheid Investor Relations
    Tel: (408) 400-8377                      Tel: (408) 400-8329
    jared.tipton@cepheid.com                 investor.relations@cepheid.com


'/>"/>
SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cepheid Reports 2009 Second Quarter Results
2. Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection
3. Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML)
4. Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control (APIC) Annual Conference
5. Cepheid Receives Health Canada License for Xpert(R) HemosIL(R) FII & FV Test
6. Blue Mountain Quality Resources Announces that Cepheid has Selected Blue Mountain Regulatory Asset Manager
7. Cepheid to Webcast Upcoming Financial Presentations
8. Cepheid Announces European Release of First On-Demand Molecular Pre-Surgical Screening Test for Simultaneous Detection of Methicillin-Sensitive and Resistant S. aureus
9. Cepheid Receives Health Canada License for First On-demand Diagnostic Test for Life-threatening MRSA and S. aureus Infections From Patient Positive Blood Culture Bottles
10. Cepheid Reports Fourth Quarter and Full Year 2008 Results
11. Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , ... January 19, 2017 , ... ... by the American Board of Dermatology and fellowship trained Mohs and cosmetic surgeon. ... Institutes of Health, Dr. Li completed his internship in internal medicine at the ...
(Date:1/19/2017)... ... January 19, 2017 , ... In 2009, Carol ... that resulted in severe facial disfiguration. After four frightening years of isolation and ... UCLA Medical Center, who removed the substances in a partial facial transplant through ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... and privacy panel system. , The Tranquility privacy panel system was designed ... office environment. Tranquility panels help reduce noise and provide the visual privacy required ...
(Date:1/19/2017)... ... , ... Sam & Associates Insurance Agency, a full service firm providing asset ... Bay Area, is launching a charity drive to raise awareness of heart disease risk ... primary killer of adult men and women in America, and is responsible for over ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... agency which serves Lawrenceville, New Jersey and the surrounding area, is inaugurating ... lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease or motor neurone ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... RATON, Fla. , Jan. 19, 2017 /PRNewswire/ ... a medical device company specializing in the treatment ... such as keloids, with superficial radiation therapy, today ... and full year 2016 financial results on Thursday, February ... The Company will hold a conference call with ...
(Date:1/19/2017)... CAMBRIDGE, England , January 19, 2017 ... MedImmune and Otsuka in the Milner Therapeutics Consortium   ... academic scientists in Cambridge   ... Inc. (NYSE: PFE ) as a partner ... join the Consortium, which enables the efficient transfer of ...
(Date:1/19/2017)... , January 18, 2017 , , Marks E-QURE ... distribution agreement, following similar agreements in ... Wound care is $2 5 ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment ... - Médica Equipos Médicos S.A.S. (TeckMedica) in Colombia for ...
Breaking Medicine Technology: